The Health Insurance Review and Assessment Service made a preannouncement of a revision plan to expand the number of reference countries used to evaluate new drugs from 7 to 9 (US, UK, Germany, France, Italy, Switzerland, Japan, Canada, Australia·A9). After opinion inquiries, the revised plan will take effect in January next year.

Although the reference countries are used to evaluate the adequacy of reimbursement of new drugs that are waived submission of pharmacoeconomic evaluation data, domestic pharmaceutical companies that own more generics than new drugs are also voicing opposition due to concerns over the next step HIRA will take afterward.

According to industry sources on the 22n